Is Evolus Inc. (EOLS) A Good Investment?

0
50

Evolus Inc. (NASDAQ:EOLS) finished Friday with a subtraction of $0.0 to close at $7.51, a downside of 0.00 percent. An average of 420,960 shares of common stock have been traded in the last five days. There was a gain of $0.62 in the past week, and it reached a new high 31 times over the past 12 months. The last 20 days have seen an average of 425,345 shares traded, while the 50-day average volume stands at 393,324.

EOLS stock has increased by 3.73% in the last month. The company shares reached their 1-month lowest point of $6.51 on 12/27/22. With the stock rallying to its 52-week high on 05/17/22, shares of the company touched a low of $5.06 and a high of $14.34 in 52 weeks. It has reached a new high 30 times so far this year and achieved 15.36% or $1.00 in price. In spite of this, the price is down -47.63% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

EOLS stock investors should be aware that Evolus Inc. (EOLS) stock had its last reported insider trading activity 86 days ago on Oct 06. In this transaction, the insider spent $344,418. 10% Owner, Medytox Inc., disposed of 6,848 shares at a price of $8.95 on Oct 05. The insider now owns more than $61,290 worth of shares. Prior to that, 10% Owner Medytox Inc. went on to Sale 24,000 shares at $10.34 each on Sep 15. An amount of $248,105 was transacted.

Valuation Metrics

Evolus Inc. (EOLS) stock’s beta is 1.86. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.03, the price-to-book (PB) ratio at 14.44.

Financial Health

The quick ratio of Evolus Inc. for the three months ended June 29 was 1.80, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.46 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $56.14 million compared to revenue of $99.67 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Evolus Inc.’s return on assets was -36.00%.

Earnings Surprise

For the three-month period that ended June 29, Evolus Inc. had $71.71 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$20.28 million in the quarter, while revenues of -$23.47 million were grew 4.19%. The analyst consensus anticipated Evolus Inc.’s latest quarter earnings to come in at -$0.24 per share, but it turned out to be -$0.28, a -16.70% surprise. For the quarter, EBITDA amounted to -$16.51 million. Shareholders own equity worth $56.25 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Evolus Inc. (EOLS) price momentum. RSI 9-day as of the close on 30 December was 61.88%, suggesting the stock is Neutral, with historical volatility in this time frame at 69.59%.

As of today, EOLS’s price is $7.05 +9.00% or $0.62 from its 5-day moving average. EOLS is currently trading +2.32% higher than its 20-day SMA and -16.09% lower than its 100-day SMA. However, the stock’s current price level is -9.30% below the SMA50 and -28.75% below the SMA200.

The stochastic %K and %D were 58.90% and 36.35%, respectively, and the average true range (ATR) was 0.41. With the 14-day stochastic at 75.19% and the average true range at 0.41, the RSI (14) stands at 55.48%. The stock has reached 0.30 on the 9-day MACD Oscillator while the 14-day reading was at 0.23.

Analyst Ratings

Needham launched coverage on Evolus Inc. (NASDAQ: EOLS) in its analyst report released on June 23, 2022. The firm assigned the stock a Buy rating. The consensus rating for Evolus Inc. (EOLS) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell EOLS, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.

What is EOLS’s price target for the next 12 months?

Analysts predict a range of price targets between $10.00 and $20.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Evolus Inc. (EOLS) stock is $15.89.

LEAVE A REPLY

Please enter your comment!
Please enter your name here